A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies

Trial Profile

A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Crizotinib (Primary) ; Dasatinib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bone metastases; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal stromal tumours; Glioblastoma; Head and neck cancer; Liver cancer; Lung cancer; Lymphoma; Malignant melanoma; Malignant thymoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Uterine cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Oct 2017 Results published in the Investigational New Drugs
    • 28 Sep 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top